Development of effective skin cancer treatment and prevention in xeroderma pigmentosum.
Xeroderma pigmentosum (XP) is a rare, recessively transmitted genetic disease characterized by increasingly marked dyspigmentation and xerosis (dryness) of sun-exposed tissues, especially skin. Skin cancers characteristically develop in sun-exposed sites at very much earlier ages than in the general population; these are often multiple and hundreds or even thousands may develop. Eight complementation groups have been identified. Seven groups, XP-A…G, are associated with defective genes encoding proteins involved in the nucleotide excision DNA repair (NER) pathway that recognizes and excises mutagenic changes induced in DNA by sunlight; the eighth group, XP-V, is associated with defective translesion synthesis (TLS) bypassing such alterations. The dyspigmentation, xerosis and eventually carcinogenesis in XP patients appear to be due to their cells' failure to respond properly to these mutagenic DNA alterations, leading to mutations in skin cells. A subset of cases, especially those in some complementation groups, may develop neurological degeneration, which may be severe. However, in most XP patients, in the past the multiple skin cancers have led to death at an early age due to either metastases or sepsis. Using either topical 5-fluorouracil or imiquimod, we have developed a protocol that effectively prevents most skin cancer development in XP patients.
Departments of Pathology and Laboratory Medicine and of Dermatology, Rutgers University - New Jersey Medical School, Newark, NJ.
W Clark
WC
Lambert
Muriel W
MW
Lambert
D017668:Age of Onset; D000634:Aminoquinolines / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D004249:DNA Damage; D004260:DNA Repair; D004273:DNA, Neoplasm / Q000235:genetics* / Q000378:metabolism; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D008545:Melanoma / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000517:prevention & control*; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000528:radiation effects; D012878:Skin Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000517:prevention & control*; D012880:Skin Pigmentation / Q000187:drug effects / Q000528:radiation effects; D014466:Ultraviolet Rays / Q000009:adverse effects; D014983:Xeroderma Pigmentosum / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics
D000634:Aminoquinolines; D016588:Anticarcinogenic Agents; D004273:DNA, Neoplasm; D000077271:Imiquimod; D005472:Fluorouracil